Monday, Jan. 8
Tuesday, Jan. 9
Wednesday, Jan. 10
Thursday, Jan. 11
Monday, Jan. 8
Welcome Remarks and Opening Keynote Lectures
6-8 p.m.
Welcome Remarks
Fred R. Hirsch, CEO, IASLC
Immunotherapy in lung cancer: The good, the bad, and the ugly
Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, New York
The role of aneuploidy during tumorigenesis
Teresa Davoli, Harvard Medical School, Boston, Massachusetts
Functional lung cancer genomics through in vivo genome editing
Monte M. Winslow, Stanford University School of Medicine, Stanford, California
Opening Reception
8-10 p.m.
Tuesday, Jan. 9
Continental Breakfast and Networking Roundtables
7-8 a.m.
Plenary Session 1: Early Steps in Lung Oncogenesis
8-10 a.m.
Elucidating lung stem cells and the initiation of lung cancer at single-cell resolution
Mark A. Krasnow, Stanford University, Stanford, California
Early steps in lung oncogenesis
Samuel Janes, University College London, London, United Kingdom
Molecular mechanisms of lung cancer development: between metabolic reprogramming and genomic instability in the field of cancerization
Pierre P. Massion, Vanderbilt University Medical Center, Nashville, Tennessee
Influence of cancer initiation on tumor progression in SCLC
Julien Sage, Stanford University School of Medicine, Stanford, California
Modeling Rb loss and pathway reactivation in lung adenocarcinoma*
David M. Feldser, University of Pennsylvania, Philadelphia, Pennsylvania
Break
10-10:30 a.m.
Plenary Session 2: Early Detection
10:30 a.m.-12:25 p.m.
Individualized risk-based lung cancer screening: The way forward
Christine D. Berg, National Cancer Institute, Bethesda, Maryland
Inflammation and immunity in pulmonary premalignancy
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, California
Intercepting lung cancer via the airway transcriptome
Avrum E. Spira, Boston University School of Medicine, Boston, Massachusetts
Gene networks, airway smoke injury, and cancer risk
Bruce A.J. Ponder, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer*
Takahiro Oike, National Cancer Institute, Besthesda, Maryland
Poster A Highlights Session
12:25-12:35 p.m.
Poster Session A / Lunch
12:40-2 p.m.
Plenary Session 3: Liquid Biopsies
2:30-3:45 p.m.
Early detection of molecular residual disease in localized lung cancer via circulating tumor DNA profiling
Maximilian Diehn, Stanford University, Stanford, California
Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study
Christopher Abbosh, University College London Cancer Institute, London, United Kingdom
ctDNA assessment of resistance and heterogeneity in EGFR mutant lung cancers
Zofia Piotrowska, Partners Cancer Care/MGH Cancer Center, Boston, Massachusetts
Break
3:45-4 p.m.
Plenary Session 4: Heterogeneity and Evolution
4-6:15 p.m.
Liquid biopsies and lung cancer evolution
Trever G. Bivona, University of California San Francisco, San Francisco, California
Tracking Lung Cancer Evolution through therapy-(TRACERx): Immune evasion, progression and adaptation
Charles Swanton, The Francis Crick Institute and University College London Cancer Institute, London, United Kingdom
Evolution of acquired resistance in EGFR-mutant NSCLC
Aaron N. Hata, Massachusetts General Hospital, Charlestown, Massachusetts
Cell-of-origin footprints in lung cancer genomes and transcriptomes
Marcin Imielinski, Weill Cornell Medical College, New York, New York
Dissecting the playbook of cancer: Genomic analysis of 100,000 human tumors reveals elaborate patterns of activation of the RTK-RAS-MAPK pathway*
Gerard Manning, Genentech, South San Francisco, California
Decoding tumor microenvironment to enhance NSCLC targeted therapy*
Haichuan Hu, MGH Cancer Center/Harvard Medical School, Charlestown, Massachusetts
Evening on Own
6:15 p.m.-
Top of page
Wednesday, Jan. 10
Continental Breakfast
7-8 a.m.
Plenary Session 5: Immunotherapy: Biomarkers and Checkpoint Blockade in NSCLC
8-10 a.m.
Immunotherapy: Biomarkers and checkpoint blockade in NSCLC
David P. Carbone, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Mechanisms of acquired resistance to immune checkpoint inhibitors in lung cancer
Katerina A. Politi, Yale University Cancer Center, New Haven, Connecticut
Immunotherapy for thoracic malignancies beyond NSCLC
Solange Peters, Centre Cordonne D'Oncologie - CHUV, Lausanne, Switzerland
Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancer*
John Wrangle, Medical University of South Carolina, Charleston, South Carolina
Investigating ectopic lymphoid aggregates in a genetically engineered mouse model of lung adenocarcinoma*
Kelli Connolly, Yale University, New Haven, Connecticut
Role of the microbiota in inflammation and lung cancer*
Ana I. Robles, National Cancer Institute, Besthesda, Maryland
Break
10-10:30 a.m.
Plenary Session 6: Vaccines, Cellular Therapy, Neoantigen Targeting
10:30 a.m.-11:20 a.m.
Allele-specific HLA loss and immune escape in lung cancer evolution
Rachel Rosenthal, University College London, London, United Kingdom
Are tumors predictable? Inherited immune variation constrains tumor evolution
Hannah K. Carter, University of California San Diego, San Diego, California
Special Lecture
11:30 a.m.-12 p.m.
Developing precision medicine–based new lung cancer therapeutics
John D. Minna, UT Southwestern Medical Center, Dallas, Texas
Lunch on Own
12 p.m.-1:30 p.m.
Plenary Session 7: Small Cell Lung Cancer
1:30-3:40 p.m.
Mechanisms of chemoresistance in SCLC
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, New York, New York
MYC drives molecular and therapeutically distinct subtype of SCLC
Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
The genomic landscape of SCLC and other neuroendocrine lung tumors
Julie George, University of Cologne, Cologne, Germany
Circulating Tumor Cells: A liquid biopsy for SCLC with multiple applications
Caroline Dive, Cancer Research UK Manchester Institute, Manchester, UK
Functional characterization and evolutionary reconstruction of small cell lung cancer transformation of EGFR-mutant lung adenocarcinomas*
June-Koo Lee, Harvard Medical School, Boston, Massachusetts
Alterations in cell junctions and neuroendocrine differentiation are key early steps in Crebbp/Ep300 mutation-driven SCLC development*
Kwon-Sik Park, University of Virginia, Charlottesville, Virginia
Break
3:40-4 p.m.
Plenary Session 8: Imaging, Radiation Oncology, Radiomics
4-5:30 p.m.
ImmunoPET imaging of DLL3 in small cell lung cancer
John T. Poirier, Memorial Sloan Kettering Cancer Center, New York, New York
Radiation therapy in lung cancer: Recent trends and future directions
Daniel R. Gomez, The University of Texas MD Anderson Cancer Center, Houston, Texas
Multiscale modeling of lung cancer
Olivier Gevaert, Stanford University, Stanford, California
Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic based therapies*
David B. Shackelford, UCLA David Geffen School of Medicine, Los Angeles, California
Poster Session B Highlights
5:30-5:40 p.m.
Poster Session B / Reception
5:40-7 p.m.
Evening on Own
7 p.m.-
Top of page
Thursday, Jan. 11
Continental Breakfast
7-8 a.m.
Plenary Session 9: Tumor Microenvironment
8-10 a.m.
Comprehensive enumeration of immune cells in the tumor microenvironment using multiplexed ion beam imaging
Michael Angelo, Stanford University School of Medicine, Stanford, California
Targeting cellular heterogeneity in lung adenocarcinoma
Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, New York
Immune contexture evolution during lung cancer carcinogenesis and its potential clinical implications
Jianjun Zhang, The University of Texas MD Anderson Cancer Center, Houston, Texas
Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkers
Sergio Quezada, University College London Cancer Institute, London, United Kingdom
Hyperspectral imaging tools capture the spatial organization of cell subsets within the tumour microenvironment*
Katey S.S. Enfield, British Columbia Cancer Research Center, Vancouver, BC, Canada
Break
10-10:15 a.m.
Plenary Session 10: Targeted Therapies
10:15 a.m.-12 p.m.
Precise inhibition of oncogenic BRAF activation
Zhan Yao, Memorial Sloan Kettering Cancer Center, New York, New York
A combined protein-protein interaction and genetic interaction map defines new and critical Kras effectors in non-small cell lung cancer*
Peter K. Jackson, Stanford University School of Medicine, Stanford, California
Progress and unanswered questions in EGFR mutation–positive lung cancer
Lecia Sequist, Massachusetts General Hospital, Boston, Massachusetts
MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer*
Shigeki Nanjo, University of California San Francisco, San Francisco, California
The art in the science of ALK positive lung cancer management
Tony S.K. Mok, Chinese University of Hong Kong, Shatin, Hong Kong
Departure
12 p.m.
*Short talk from proffered abstract
Top of page
